Great article, would you like

Like
Comment
Favorite

Great article, would you like to share it?

Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability

(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with $Sanofi(GCVRZ)$ for COVID-19 vaccines in exchange for a st

Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":304497975070864,"tweetId":"304497975070864","gmtCreate":1715374823986,"gmtModify":1715378950032,"author":{"id":4178343809649462,"idStr":"4178343809649462","authorId":4178343809649462,"authorIdStr":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Great article, would you like to share it?</p></body></html>","htmlText":"<html><head></head><body><p>Great article, would you like to share it?</p></body></html>","text":"Great article, would you like to share it?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/304497975070864","repostId":2434844398,"repostType":2,"repost":{"id":"2434844398","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1715338729,"share":"https://www.laohu8.com/m/news/2434844398?lang=&edition=full","pubTime":"2024-05-10 18:58","market":"us","language":"en","title":"Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability","url":"https://stock-news.laohu8.com/highlight/detail?id=2434844398","media":"Reuters","summary":"(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with $Sanofi(GCVRZ)$ for COVID-19 vaccines in exchange for a st","content":"<html><head></head><body><p>(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker&#39;s market value.</p><p>Novavax’s U.S.-listed shares soared over 202% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b48e5547ae5b5695bb762a993b997e33\" tg-width=\"780\" tg-height=\"633\"/></p><p>In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.</p><p>Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax&#39;s Matrix-M adjuvant.</p><p>Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.</p><p>Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.</p><p>&#34;We&#39;re excited by the prospect of combining Novavax&#39;s adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)&#34;, Sanofi&#39;s head of vaccines R&amp;D, Jean-Francois Toussaint, said in a statement.</p><p>Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.</p><p>Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.</p><p>Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D&#39;Souza)</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-05-10 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker&#39;s market value.</p><p>Novavax’s U.S.-listed shares soared over 202% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b48e5547ae5b5695bb762a993b997e33\" tg-width=\"780\" tg-height=\"633\"/></p><p>In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.</p><p>Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax&#39;s Matrix-M adjuvant.</p><p>Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.</p><p>Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.</p><p>&#34;We&#39;re excited by the prospect of combining Novavax&#39;s adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)&#34;, Sanofi&#39;s head of vaccines R&amp;D, Jean-Francois Toussaint, said in a statement.</p><p>Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.</p><p>Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.</p><p>Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D&#39;Souza)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","SNYNF":"Sanofi","NVAX":"诺瓦瓦克斯医药","BK4585":"ETF&股票定投概念","BNTX":"BioNTech SE","BK4139":"生物科技","BK4588":"碎股","SNY":"赛诺菲安万特","BK4007":"制药"},"source_url":"https://finance.yahoo.com/news/1-frances-sanofi-covid-19-061951520.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2434844398","content_text":"(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker's market value.Novavax’s U.S.-listed shares soared over 202% in premarket trading.In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax's Matrix-M adjuvant.Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.\"We're excited by the prospect of combining Novavax's adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)\", Sanofi's head of vaccines R&D, Jean-Francois Toussaint, said in a statement.Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D'Souza)","news_type":1},"isVote":1,"tweetType":1,"viewCount":221,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":35,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}